SCHEMBL4255964

SCHEMBL4255964

CC(=O)c1cnc2ccc(/C=C3\SC(=O)NC3=O)cn12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.54
PIK3CA P42336 1/20 0.54
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
HTT P42858 1/20 0.48
PIM1 P11309 7/20 0.48
PIM2 Q9P1W9 5/20 0.48
HPGD P15428 3/20 0.48
GSK3B P49841 3/20 0.48
AKR1B1 P15121 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
CISD1 Q9NZ45 2/20 0.47
MAOA P21397 1/20 0.47
NAT1 P18440 1/20 0.46
PIM3 Q86V86 1/20 0.46
MTOR P42345 1/20 0.46
MGAM O43451 1/20 0.46
GAA P10253 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4255970 1.00 PIK3CG (0.54) PIK3CGPIK3CARAB9ANPC1HTT
SCHEMBL4254082 0.87 RAB9A (0.51) PIK3CGPIK3CARAB9ANPC1HTT
SCHEMBL4257055 0.87 PIK3CG (0.50) PIK3CGPIK3CARAB9ANPC1HTT
SCHEMBL4254079 0.87 RAB9A (0.51) PIK3CGPIK3CARAB9ANPC1HTT
SCHEMBL4257050 0.87 PIK3CG (0.50) PIK3CGPIK3CARAB9ANPC1HTT
SCHEMBL4259167 0.86 PIK3CG (0.51) PIK3CGPIK3CARAB9ANPC1HTT
SCHEMBL4260643 0.86 PIK3CG (0.51) PIK3CGPIK3CARAB9ANPC1HTT
SCHEMBL4260636 0.85 PIK3CG (0.47) PIK3CGPIK3CARAB9ANPC1HTT
SCHEMBL4257913 0.85 PIK3CG (0.47) PIK3CGPIK3CARAB9ANPC1HTT
SCHEMBL4250648 0.85 PIK3CG (0.53) PIK3CGPIK3CARAB9ANPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 US claimed
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 US disclosed
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 US disclosed
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 US disclosed
WO-2008014219-A2 THIOZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215818-A1 THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS PIK3CD, PI4KA, PIP4K2A PIK3CG 5/4885PIK3CA 15/4885RAB9A 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.